Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials
Cancer Research and Treatment · 2025
DOI: 10.4143/crt.2024.652 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Jaewon Hyung und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Biliary Tract Neoplasms. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: NCI NIH HHS, Asan Institute for Life Sciences, Asan Medical Center.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PurposeWhile fluoropyrimidine-based chemotherapy regimens are recommended second-line treatment for patients with advanced biliary tract cancer (BTC), there have been no studies comparing different regimens head-to-head.Materials and Methods We performed individual patient-level meta-analysis based on data from the intention-to-treat population of the phase 2b NIFTY trial (liposomal irinotecan [nal-IRI] plus fluorouracil and leucovorin [5-FU/LV] vs. 5-FU/LV; NCT03542508) and the phase 2 FIReFOX trial (modified oxaliplatin plus 5-FU/LV [mFOLFOX] vs. modified irinotecan plus 5-FU/LV [mFOLFIRI]; NCT03464968). Pairwise log-rank tests and multivariable analysis using Cox proportional hazards modeling with shared frailty to account for the trial's effect were used to compare overall survival (OS) between regimens.
Results
A total of 277 patients were included. The nal-IRI plus 5-FU/LV group (n=88) showed significantly better OS compared to the mFOLFOX group (n=49, pairwise log-rank, p=0.02), and mFOLFIRI group (n=50, p=0.03). Multivariable analysis showed consistent trends in OS with adjusted hazard ratios of 1.39 (mFOLFOX vs. nal-IRI plus 5-FU/LV: 95% confidence interval [CI], 0.93 to 2.07; p=0.11) and 1.36 (mFOLFIRI vs. nal-IRI plus 5-FU/LV: 95% CI, 0.92 to 2.03; p=0.13), respectively. Compared to the 5-FU/LV group, the mFOLFOX group and the mFOLFIRI group did not show differences in terms of OS (pairwise log-rank p=0.83 and p=0.58, respectively). The nal-IRI plus 5-FU/LV group experienced more frequent diarrhea, while the mFOLFOX group experienced peripheral neuropathy.
Conclusion
Nal-IRI plus 5-FU/LV showed favorable survival outcomes compared to mFOLFOX, mFOLFIRI, or 5-FU/LV. The safety profiles of these regimens should be considered along with efficacy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Division of Oncology, Department of Internal Medicine, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
- Division of Hematology and Oncology, Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea.
- Division of Hematology and Oncology, Department of Internal Medicine, Chungnam National University Hospital, Chungnam National University College of Medicine, Daejeon, Korea.
- Clinical Research Center, Asan Institute for Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Förderung
- NCI NIH HHS
- Asan Institute for Life Sciences, Asan Medical Center
Zitieren
APA
Hyung, J., Kang, M., Kim, I., Kim, K. P., Ryoo, B. Y., Cheon, J., Ryu, H., Lee, J. S., Kim, J. W., Choi, I. S., Park, J. H., Abou-Alfa, G. K., Kim, J. W., & Yoo, C. (2025). Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials. Cancer Research and Treatment. https://doi.org/10.4143/crt.2024.652
Vancouver
Hyung J, Kang M, Kim I, Kim KP, Ryoo BY, Cheon J, et al. Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials. Cancer Research and Treatment. 2025. doi:10.4143/crt.2024.652
BibTeX
@article{Hyung2025,
author = {Hyung, Jaewon and Kang, Minsu and Kim, Ilhwan and Kim, Kyu-Pyo and Ryoo, Baek-Yeol and Cheon, Jaekyung and Ryu, Hyewon and Lee, Ji Sung and Kim, Ji-Won and Choi, In Sil and Park, Jin Hyun and Abou-Alfa, Ghassan K and Kim, Jin Won and Yoo, Changhoon},
title = {Second-Line Fluoropyrimidine-Based Chemotherapy in Advanced Biliary Tract Cancer: A Meta-analysis Based on Individual Patient-Level Data of Randomized Trials},
journal = {Cancer Research and Treatment},
year = {2025},
doi = {10.4143/crt.2024.652}
}
EUVIMED